The challenges of immunogenicity in developing biosimilar products

被引：0

作者：

Wadhwa, Meenu ^{[1
]}

Thorpe, Robin ^{[1
]}

机构：

[1] Natl Inst Biol Stand & Controls, Biotherapeut Grp, Potters Bar EN6 3QG, Herts, England

来源：

IDRUGS | 2009年 / 12卷 / 07期

关键词：

Binding antibody; biological; biosimilar; follow-on-biological; immunogenicity; neutralizing antibody; safety monitoring; subsequent entry biological;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Unwanted immunogenicity is a significant issue affecting most biotherapeutic products, including subsequent entry biological (SEB) medicines. Such immunogenicity can be associated with adverse reactions and can cause impaired clinical responses to the biotherapeutic. This feature article provides an overview of the challenges facing the biotechnology industry with regard to the prediction and assessment of immunogenicity of SEBs and, in particular, biosimilar products. In addition, the available guidance on assessing the immunogenicity of biotherapeutic products is discussed.

引用

页码：440 / 444

页数：5

共 8 条

[1]

[Anonymous], 2005, GUID SIM BIOL MED PR

[2]

*EUR MED AG, 2007, GUID IMM ASS BIOT TH

[3]

European Medicines Agency, 2009, CONC PAP IMM ASS MON

[4]

European Medicines Agency, 2009, GUID NONCL CLIN DEV

[5]

European Medicines Agency, 2006, GUID SIM BIOL MED PR

[6] The challenge of biosimilars [J].

Mellstedt, H. ;

Niederwieser, D. ;

Ludwig, H. .

ANNALS OF ONCOLOGY, 2008, 19 (03) :411-419

[7] How similar do 'biosimilars' need to be? [J].

Schellekens, H .

NATURE BIOTECHNOLOGY, 2004, 22 (11) :1357-1359

[8] Toward biosimilar monoclonal antibodies [J].

Schneider, Christian K. ;

Kalinke, Ulrich .

NATURE BIOTECHNOLOGY, 2008, 26 (09) :985-990

← 1 →